Archer Materials Advances Biosensor Medical Device Program to Beta Prototype Stage, Shares Jump 3%

MT Newswires Live

May 15

Archer Materials (ASX:AXE) advanced to the next stage of product development via the construction of its beta prototype Biosensor platform suitable for preclinical validation, after its integrated alpha prototype medical device achieved clinical-grade potassium sensing accuracy, according to a Friday Australian bourse filing.

It plans to develop multiple versions of the beta prototype. The first beta prototype system is expected to become available for testing in the coming months. Early feasibility testing for monitoring lithium levels in blood is underway.

Additional optimization and validation are planned throughout the second half of the year, with the target of a fully optimized beta prototype for use in trials in 2027.

Its shares climbed 3% in recent trading on Friday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2635766347"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2635766347\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2635766347?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-15 10:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635766347","market":"fut","top_or_hot":-1,"title":"Archer Materials Advances Biosensor Medical Device Program to Beta Prototype Stage, Shares Jump 3%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/AXE.AU\">Archer Materials</a> (ASX:AXE) advanced to the next stage of product development via the construction of its beta prototype Biosensor platform suitable for preclinical validation, after its integrated alpha prototype medical device achieved clinical-grade potassium sensing accuracy, according to a Friday Australian bourse filing.</p><p>It plans to develop multiple versions of the beta prototype. The first beta prototype system is expected to become available for testing in the coming months. Early feasibility testing for monitoring lithium levels in blood is underway.</p><p>Additional optimization and validation are planned throughout the second half of the year, with the target of a fully optimized beta prototype for use in trials in 2027.</p><p>Its shares climbed 3% in recent trading on Friday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Archer Materials Advances Biosensor Medical Device Program to Beta Prototype Stage, Shares Jump 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArcher Materials Advances Biosensor Medical Device Program to Beta Prototype Stage, Shares Jump 3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-15 10:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/AXE.AU\">Archer Materials</a> (ASX:AXE) advanced to the next stage of product development via the construction of its beta prototype Biosensor platform suitable for preclinical validation, after its integrated alpha prototype medical device achieved clinical-grade potassium sensing accuracy, according to a Friday Australian bourse filing.</p><p>It plans to develop multiple versions of the beta prototype. The first beta prototype system is expected to become available for testing in the coming months. Early feasibility testing for monitoring lithium levels in blood is underway.</p><p>Additional optimization and validation are planned throughout the second half of the year, with the target of a fully optimized beta prototype for use in trials in 2027.</p><p>Its shares climbed 3% in recent trading on Friday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AXE.AU","symbol_name":"ARCHER MATERIALS LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2635766347","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635766347","pubTimestamp":1778813492,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Archer Materials (ASX:AXE) advanced to the next stage of product development via the construction of its beta prototype Biosensor platform suitable for preclinical validation, after its integrated alp","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AXE.AU":"ARCHER MATERIALS LTD","BK7069":"半导体产品","UYM":"基础材料指数ETF-ProShares两倍做多"},"translate_title":"Archer Materials将生物传感器医疗设备项目推进至测试原型阶段，股价上涨3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AXE.AU":1,"UYM":1.5,"SSI":1.5},"content_text":"Archer Materials (ASX:AXE) advanced to the next stage of product development via the construction of its beta prototype Biosensor platform suitable for preclinical validation, after its integrated alpha prototype medical device achieved clinical-grade potassium sensing accuracy, according to a Friday Australian bourse filing.It plans to develop multiple versions of the beta prototype. The first beta prototype system is expected to become available for testing in the coming months. Early feasibility testing for monitoring lithium levels in blood is underway.Additional optimization and validation are planned throughout the second half of the year, with the target of a fully optimized beta prototype for use in trials in 2027.Its shares climbed 3% in recent trading on Friday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}